Skip to main content

Table 3 Clinical characteristics of T2DM patients before and after nateglinide treatment (n = 60)

From: Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Parameters Before treatment n = 60 After treatment n = 60 P values
BMI (kg/m2) 25.41 ± 3.54 25.33 ± 3.11 0.896
WHR 0.92 ± 0.06 0.91 ± 0.06 0.363
FPG (mmol/L) 10.41 ± 1.23 7.25 ± 1.21 0.000*
PPG (mmol/L) 14.56 ± 2.76 9.38 ± 2.61 0.000*
FINS (mU/L) 7.56 ± 4.39 9.51 ± 3.46 0.008*
PINS (mU/L) 30.31 ± 17.10 47.21 ± 15.16 0.000*
HOMA-IR 3.57 ± 1.30 2.72 ± 1.41 0.001*
HOMA-β 25.73 ± 14.5 60.32 ± 21.15 0.000*
HbA1c (%) 9.31 ± 1.87 7.89 ± 0.81 0.000*
TG (mmol/L) 2.25 ± 1.38 1.86 ± 1.23 0.105
TC (mmol/L) 5.21 ± 1.29 4.31 ± 1.09 0.000*
HDL-c (mmol/L) 1.38 ± 0.75 1.45 ± 0.59 0.571
LDL-c (mmol/L) 3.85 ± 1.78 3.42 ± 1.07 0.111
  1. BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β Homeostasis model assessment for islet β cell function, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol
  2. Data are expressed as (mean ± SD). P values are determined by the paired Student’s t test. *P < 0.05